Drug Type TCR therapy |
Synonyms TCRTESOA2, TCRTESOA2Axis Therapeutics |
Target- |
Mechanism T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 3 | TW | 18 Oct 2021 | |
Advanced Malignant Solid Neoplasm | Phase 3 | - | 11 Aug 2021 | |
Head and Neck Neoplasms | Preclinical | CN | 06 Nov 2021 | |
Hepatocellular Carcinoma | Preclinical | CN | 06 Nov 2021 | |
Lung Cancer | Preclinical | CN | 06 Nov 2021 | |
Sarcoma | Preclinical | CN | 06 Nov 2021 | |
Squamous Cell Carcinoma | Preclinical | CN | 06 Nov 2021 |